StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Arcus Biosciences — Operating income (loss) by Quarter

Arcus Biosciences — Operating income (loss) ($M) ($M)

QuarterlyAnnual

Gilead Sciences Arcus Biosciences — Operating income (loss): -$96M in Q2 2026, up 1,100.0% from a year earlier.

Latest, Q2 2026
-96
Period ended Jun 30, 2026
Change on a year earlier
+1,100.0%
-8 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

Source: Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗

Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedArcus Biosciences — Operating income (loss) ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026-96+1,100.0%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026-134+9.8%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗
Q4 2025Dec 31, 2025-114+10.7%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Q3 2025Sep 30, 2025-142+35.2%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗
Q2 2025Jun 30, 2025-8-92.5%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Q1 2025Mar 31, 2025-122+662.5%Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗
Q4 2024Dec 31, 2024-103+13.2%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Q3 2024Sep 30, 2024-105+31.3%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗
Q2 2024Jun 30, 2024-106+27.7%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-08-06) ↗
Q1 2024Mar 31, 2024-16-81.4%Arcus Biosciences (RCUS) Form 10-Q (filed 2025-05-06) ↗
Q4 2023Dec 31, 2023-91+23.0%Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗
Q3 2023Sep 30, 2023-80+14.3%Arcus Biosciences (RCUS) Form 10-Q (filed 2024-11-06) ↗
Q2 2023Jun 30, 2023-83+20.3%Arcus Biosciences (RCUS) Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023-86+28.4%Arcus Biosciences (RCUS) Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022-74-126.3%Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗
Q3 2022Sep 30, 2022-70-10.4%SEC Filing ↗

Cite this data

StockData. (2026). Gilead Sciences Arcus Biosciences — Operating income (loss) ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-op-inc

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.